Ophthalmic topical therapeutics refer to pharmaceutical products that are applied directly to the eyes, typically in the form of eye drops or ointments, to treat various eye conditions and disorders. These products can be used to manage conditions such as glaucoma, infections, dry eye, and inflammation.
Santen Pharmaceutical Acquired the ophthalmic business of Chemo Unipharm, expanding its portfolio of glaucoma and dry eye treatments.
Sun Pharmaceutical Industries Launched a biosimilar version of Lucentis (ranibizumab) for treating age-related macular degeneration, potentially disrupting the market with a more affordable option.
Novartis Received FDA approval for Vuity (pilocarpine), the first prescription eye drop approved to treat presbyopia, a common age-related vision condition.
Alcon Partnered with Vergence Therapeutics to develop and commercialize gene therapy treatments for eye diseases like Leber's hereditary optic neuropathy.
Akorn Operating Company Launched a generic version of Restasis (cyclosporine), a leading dry eye treatment, offering a more affordable option for patients.
Ophthalmic Topical Therapeutics Market Highlights:
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)